Skip to main content
. Author manuscript; available in PMC: 2020 Nov 20.
Published in final edited form as: Arch Pathol Lab Med. 2017 Nov 16;142(2):198–207. doi: 10.5858/arpa.2016-0483-OA

Figure 2.

Figure 2.

Analysis I: blood collection tube (BCT) comparison. A, Circulating tumor cell (CTC) candidate cells enumerated per test included high-definition CTC and marginal CTC populations as defined in Materials and Methods: CTC-Small, CTC-LowCK, and CTC-Ap. P < .001: Cell-free DNA (CfDNA) BCT versus EDTA, citrate, or heparin BCTs. B, Total negative events detected per test: total number of negative events per total number of retained cells in 1 test of 2 slides per blood sample. P<.001: CfDNA BCT versus EDTA, citrate, or heparin BCTs; EDTA BCT versus citrate BCT; EDTA BCT versus heparin BCT. C, Number of total retained cells as estimated by the DAPI nuclear stain. P < .001: heparin BCT versus CfDNA, EDTA, or citrate BCTs. D, Ratio of positive to negative events per test. Positive events were defined as the total number of candidate cells detected per total number of retained cells. P < .001: CfDNA BCT versus EDTA, citrate, or heparin BCTs. Friedman test was used to detect differences in BCTs across patient samples, followed by post hoc analysis using Dunn tests. Median and interquartile range are indicated. Abbreviation: DAPI, 4´,6-diamidino-2-phenylindole, dihydrochloride.